JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

Strona główna・Stock List・Geron Corp

Geron Corp

Open

SectorHealthcare

1.21 -3.2

Buy Sell

Overview

Share price change

24h

Current

Min

1.2

Max

1.28

Key metrics
By Trading Economics
Income	3.5M -16M
Sales	9.4M 49M
Profit margin	-33.394
Employees	229
EBITDA	9.2M -7.6M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+177.78% upside

Dividends
By Dow Jones
Next Earnings	5 lis 2025

Market Stats
By TradingEconomics
Market Cap	46M 817M
Previous open	4.41
Previous close	1.21

News Sentiment

By Acuity

84%

16%

350 / 373 Ranking in Healthcare

Geron Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 lis 2025, 22:13 UTC

Earnings

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2 lis 2025, 21:23 UTC

Earnings

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2 lis 2025, 23:43 UTC

Market Talk

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2 lis 2025, 23:34 UTC

Market Talk

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2 lis 2025, 21:00 UTC

Earnings

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2 lis 2025, 21:00 UTC

Earnings

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2 lis 2025, 21:00 UTC

Earnings

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2 lis 2025, 20:55 UTC

Earnings

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2 lis 2025, 20:55 UTC

Earnings

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2 lis 2025, 20:55 UTC

Earnings

Westpac FY Business Lending Up 15% on Year>WBC.AU

2 lis 2025, 20:46 UTC

Earnings

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2 lis 2025, 20:46 UTC

Earnings

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2 lis 2025, 20:45 UTC

Earnings

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2 lis 2025, 20:44 UTC

Earnings

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2 lis 2025, 20:43 UTC

Earnings

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2 lis 2025, 20:42 UTC

Earnings

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2 lis 2025, 20:41 UTC

Earnings

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2 lis 2025, 20:40 UTC

Earnings

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2 lis 2025, 20:39 UTC

Earnings

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2 lis 2025, 20:37 UTC

Earnings

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2 lis 2025, 20:37 UTC

Earnings

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2 lis 2025, 20:37 UTC

Earnings

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2 lis 2025, 20:36 UTC

Earnings

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2 lis 2025, 20:35 UTC

Earnings

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2 lis 2025, 20:35 UTC

Earnings

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2 lis 2025, 20:35 UTC

Earnings

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2 lis 2025, 20:34 UTC

Earnings

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2 lis 2025, 20:33 UTC

Earnings

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2 lis 2025, 14:27 UTC

Earnings

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2 lis 2025, 14:25 UTC

Earnings

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Peer Comparison

Price change

Geron Corp Forecast

Price Target

By TipRanks

177.78% upside

12 Months Forecast

Average 3.5 USD 177.78%

High 5 USD

Low 1.5 USD

Based on 6 Wall Street analysts offering 12 month price targets forGeron Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Geron Corp - Dist in the past 3 months.

Sentiment

By Acuity

350 / 373 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.